IP Library Granted Patent US 11,241,239
Granted Patent B2
US 11,241,239 · App. 16/413,090 · Granted Feb 8, 2022

Occlusive medical device with charged polymer coating

Inventors: Hong Cao (Maple Grove, MN); Dongming Hou (Plymouth, MN); Hongxia Zeng (Maple Grove, MN)
Assignee: Boston Scientific Scimed, Inc.
A61B17/12177A61B17/12122A61B17/12172A61L31/10A61L33/068A61B2017/00632
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,239
App. No.
16/413,090
Granted
Feb 8, 2022
Kind
B2
Abstract

An occlusive implant includes an expandable framework that is configured to shift between a collapsed configuration and an expanded configuration. An occlusive member is disposed along at least a portion of the expandable framework. At least part of the occlusive implant is configured to repel fibrinogen. In some cases, the occlusive implant may be configured for placement within a left atrial appendage (LAA) of a patient's heart.

Claims (35)

1. An occlusive implant, comprising:

an expandable framework configured to shift between a collapsed configuration and an expanded configuration; and

an occlusive member disposed along at least a portion of the expandable framework;

a first negatively charged coating, wherein at least part of the occlusive implant is adapted to repel fibrinogen,

a second positively charged coating, wherein at least part of the occlusive implant is adapted to attract fibrinogen,

wherein a portion of the occlusive member is between the first coating and the second coating.

2. The occlusive implant of claim 1 , wherein the occlusive implant has a leading edge, and an area of the occlusive member proximate the leading edge is treated to repel fibrinogen.

3. The occlusive implant of claim 1 , wherein the expandable framework includes a central structure, and an area of the occlusive member proximate the central structure is treated to repel fibrinogen.

4. The occlusive implant of claim 1 , wherein at least part of the occlusive implant is configured to carry a negative charge at neutral pH.

5. The occlusive implant of claim 1 , wherein at least part of the occlusive implant includes a polymer that is negatively charged as a consequence of exposure to neutral pH.

6. The occlusive implant of claim 5 , wherein the polymer that is negatively charged at neutral pH covers at least part of the occlusive member.

7. The occlusive implant of claim 5 , wherein the polymer that is negatively charged at neutral pH is spray coated onto the occlusive member.

8. The occlusive implant of claim 5 , wherein the polymer that is negatively charged at neutral pH is physically blended with a material forming the occlusive member.

9. The occlusive implant of claim 5 , wherein the polymer that is negatively charged at neutral pH is provided as a copolymer with a material forming the occlusive member.

10. The occlusive implant of claim 1 , wherein the positively charged coating is polymeric and covers at least a portion of the expandable framework.

11. The occlusive implant of claim 1 , wherein the occlusive member is formed of polyethylene terephthalate (PET).

12. The occlusive implant of claim 1 , wherein the expandable framework includes a plurality of anchor members extending radially outward from the expandable framework.

13. The occlusive implant of claim 12 , wherein the expandable framework and the plurality of anchor members are formed from a unitary tubular member.

14. The occlusive implant of claim 1 , wherein the expandable framework, in the expanded configuration, is configured to fit into a left atrial appendage (LAA) of a patient's heart.

15. The occlusive implant of claim 1 , wherein a second part of the occlusive implant not configured to repel fibrinogen is configured to attract fibrinogen.

16. A medical implant adapted to occlude a left atrial appendage (LAA) of a patient's heart, the medical implant comprising:

an expandable framework configured to shift between a collapsed configuration and an expanded configuration;

an occlusive member extending over and supported by at least a portion of the expandable framework; and

a first negatively charged coating that is configured to repel fibrinogen, the first coating disposed over at least part of the occlusive member,

a second positively charged coating that is configured to attract fibrinogen, the second coating disposed over at least part of the occlusive member,

wherein a portion of the occlusive member is between the first coating and the second coating.

17. The medical implant of claim 16 , wherein the first coating that is configured to repel fibrinogen comprises a polymer that is negatively charged as a consequence of exposure to neutral pH.

18. The medical implant of claim 16 , wherein the occlusive implant has a leading edge, and the first coating that is configured to repel fibrinogen extends over the leading edge.

19. The medical implant of claim 16 , wherein the expandable framework includes a central structure, and the first coating that is configured to repel fibrinogen extends over the central structure.

20. A medical implant adapted to occlude a left atrial appendage (LAA) of a patient's heart, the medical implant comprising:

an expandable framework configured to shift between a collapsed configuration and an expanded configuration;

an occlusive member extending over and supported by at least a portion of the expandable framework;

a first negatively charged coating disposed over a first part of the occlusive member, the first coating being configured to repel fibrinogen; and

a second positively charged coating disposed over a second part of the occlusive member, the second coating being configured to attract fibrinogen;

wherein a portion of the occlusive member is between the first coating and the second coating.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: CAO, HONG; HOU, DONGMING; ZENG, HONGXIA
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 049748/0352 →
Continuity (2)
Provisional Application 62671549 · May 15, 2018
Related Publication 20190350591A1 · Nov 21, 2019
Cited By (4)
US 12,256,938 US 12,268,394 US 12,376,861 US 12,714,432